Oxidative stress and antioxidant therapy in Parkinson's disease

Progress in Neurobiology

Volumn 48, Issue 1, 1996, Pages 1-19

  Ebadi, Manuchair ^a   Srinivasan, Shashi K ^a   Baxi, Mayur D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; BRAIN DERIVED NEUROTROPHIC FACTOR; FREE RADICAL; HYDROGEN PEROXIDE; IRON; MAZINDOL; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN 3; NEUROTROPHIN 4; NOMIFENSINE; OXIDOPAMINE; SELEGILINE;

ANIMAL MODEL; ANIMAL TISSUE; DOPAMINERGIC SYSTEM; HUMAN; HUMAN TISSUE; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030001780     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-0082(95)00029-1     Document Type: Review

References (247)

1. Adams J.D.Jr., Klaidman L.K., Odunze I.N., Shen H.C. and Miller C.A. (1991) Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Molec. Chem. Neuropath. 14, 213-226.
2. Agid Y., Ruberg M., Javoy-Agid F., Hirsch E., Raisman-Vozari R., Vyas S., Faucheux B., Michel P., Kastner A., Blanchard V., Damier P., Villares J. and Zhang P. (1993) Are dopaminergic neurons selectively vulnerable to Parkinson's disease?. Adv. Neurol. 60, 148-164.
3. Altar C.A., Boylan C.B., Jackson C., Hershenson S., Miller J., Wiegand S.J., Lindsay R.M. and Hyman C. (1992) Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natn. Acad. Sci. U.S.A. 89, 11347-11351.
4. Amara S. (1993) Neurotransmitter transporters: Recent progress. A. Rev. Neurosci. 16, 73-93.
5. Arai Y., Kimura H. and Maeda T. (1986) Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method. Neuroscience 19, 905-925.
6. Baker G.B. and Coutts R.T. (1989) Metabolism of monoamine oxidase inhibitors. Prog. Neuropsychapharmac. Biol. Psychiat. 13, 395-403.
7. Barbeau, A. (1961) Biochemistry of Parkinson's disease. In: Int. Congr. Neurol. Rome. p. 152. Ed. G. Alema. Excerpta Medica: Amsterdam.
8. Barbeau A. (1984) Manganese and extrapyramidal disorders. Neurotoxicology 5, 13-36.
9. Berry M.D., Juorio A.V. and Paterson I.A. (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog. Neurobiol. 42, 375-391.
10. Biagini G., Zoli M., Fuxe K. and Agnati L.F. (1993) L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. NeuroReport 4, 955-958.
11. Bieri J.G., Corash L. and Hubbard V.S. (1983) Medical uses of vitamin E. New Engl. J. Med. 308, 1063-1071.
12. Bindoff L.A., Birch-Machin M., Cartlidge N.E.F., Parker W.D.Jr. and Turnbull D.M. (1989) Mitochondrial function in Parkinson's disease. Lancet 2, 49.
13. Birkmayer W. and Hornykiewicz O. (1961) Der L-3,4-dioxyphenylalanin (L-DOPA) effekt bei der Parkinson akinese. Wien. Klin. Wochenschr. 73, 787-788.
14. Birkmayer W., Riederer P., Youdim M.B.H. and Lindier W. (1975) The potentiation of the anti-akinetic effect of L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J. Neural. Transm. 36, 303-326.
15. Birkmayer W., Riederer P., Ambrozi L. and Youdim M.B.H. (1977) Implications of combine treatment with 'madopar' and L-deprenyl in Parkinson's disease. Lancet 1, 439-443.
16. Birkmayer W., Riederer P. and Youdim M.B.H. (1982) (-)Deprenyl in the treatment of Parkinson's disease. Clin. Neuropharmac. 5, 195-230.
17. Birkmayer W., Knoll J., Riederer P. and Youdim M.B.H. (1983) Deprenyl leads to prolongation of L-DOPA efficacy in Parkinson's disease. Mod. Prob. Pharmacopsychiat. 19, 170-177.
18. Birkmayer W., Knoll J., Riederer P., Youdim M.B.H., Hars V. and Marton J. (1985) Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson's disease: A long term study. J. Neural. Transm. 64, 113-127.
19. Bond P.A. and Cundall R.L. (1977) Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clinica Chim. Acta 80, 317-326.
20. Bonorden, W. R. and Pariza, M. W. (1994) Antioxidant nutrients and protection from free radicals. In: Nutritional Toxicology, pp. 19-48. Eds. F. N. Kotsonis, M. Mackey and J. Hjelle. Raven Press, Ltd.: New York.
21. Bormann J. (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmac. 166, 591-592.
22. Bowling A.C., Mutisya E.M., Walker L.C., Price D.L., Cork L.C. and Beal M.F. (1993) Age-dependent impairment of mitochondrial function in primate brain. J Neurochem. 60, 1964-1967.
23. Brin M.F., Fetell M.R., Green P.H.A., Kayden H.J., Hays A.P., Behrens M.M. and Baker H. ( 1985) Blind loop syndrome, vitamin E malabsorption, and spinocerebellar degeneration. Neurology 35, 338-342.
24. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M. and Kopin I.J. (1983) A primate model of Parkinsonism; selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natn. Acad. Sci. U.S.A. 80, 4546-4550.
25. Cadet J.L. (1988) Free radical mechanisms in the central nervous system: An overview. Int. J. Neurosci. 40, 13-18.
26. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H. and Rosengren E. (1991) The neuromelanin of the human substantia nigra. Biochim. biophys. Acta. 1097, 152-160.
27. Ceballos I., Sinet P.M., Nicole A., Lafon M., Hirsch E., Javoy-Agid F. and Agid Y. (1990) Superoxide dismutase and Parkinson's disease. Lancet 1, 1035-1036..
28. Cesura A.M. and Pletscher A. (1992) The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 38, 171-297.
29. Chiba K., Trevor A. and Castagnoli N. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574-578.
30. Chiueh C.C. Miyake H. and Peng M.-T. (1993) Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. Adv. Neurol. 60, 251-258.
31. Cohen G. (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5, 77-82.
32. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C. and Yahr M.D. (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106, 209-214.
33. Cowlishaw B. (1962) The oxidation of the lipids of the erythrocyte. Biochem. J. 83, 445-450.
34. D'Amato R.J., Alexander G.M., Schwartzman R.J., Kitt C.A., Price D.L. and Snyder S.H. (1987) Evidence for neuromelanin involvement in MPTP induced neurotoxicity. Nature 327, 324-326.
35. D'Amato R.J., Benham D.F. and Snyder S.H. (1987) Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of Parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J. Neurochem. 48, 653-658.
36. Date I., Notter M.F.D., Felten S.Y. and Felton D.L. (1990) MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). Brain Res. 526, 156-160.
37. De Erausquin G.A., Costa E. and Hanbauer I. (1994) Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol. Rev. 46, 467-482.
38. Demopoulos H.B., Flamm E.S., Pietronegro D.D. and Seligman M.L. (1980) The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol. Scand. Suppl. 492, 91-119.
39. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P. and Marsden C.D. (1987) Increased nigral iron content in postmortem Parkinsonian brain. Lancet 2, 1219-1220.
40. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P. and Marsden C.D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
41. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P. and Marsden C.D. (1989) Increased nigra iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
42. Dexter D.T., Carayon A. and Vidailhet M. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
43. Dexter D.T., Carayon A. and Javoy-Agid F. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
44. Dexter D.T., Nanayakkara I., Goss-Sampson M.A., Muller D.P.R., Harding A.E., Marsden C.D. and Jenner P. (1994) Nigral dopaminergic cell loss in vitamin E deficient rats. NeuroReport 5, 1773-1776.
45. Dillard C.J., Dumelin E.E. and Tappel A.L. (1977) Effect of vitamin E on expiration of pentane and ethane by the rat. Lipids 12, 109-114.
46. DiMonte D.A., Sandy M.S., DeLanney L.E., Jewell S.A., Chan P., Irwin I. and Langston J.W. (1993) Age-dependent changes in mitochondrial energy production in striatum and cerebellum of the monkey brain. Neurodegeneration 2, 93-99.
47. DiMonte D.A., Sandy M.S., Jewell S.A., Adornato B., Tanner C.M. and Langston J.W. (1993) Oxidative phosphorylation by intact muscle mitochondria in Parkinson's disease. Neurodegeneration 2, 275-281.
48. Donnelly C.H. and Murphy D.L. (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26, 852-858.
49. Earle K.M. (1968) Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed tissue. J. Neuropath. Exp. Neurol. 27, 1-14.
50. Egashira T. (1976) Studies on monoamine oxidase. XVIII. Enzymic properties of placental monoamine oxidase. Jap. J. Pharmacol. 26, 493-500.
51. Elias E., Muller D.P.R. and Scott J. (1981) Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E. Lancet 2, 1319-1321.
52. Elizan, T. S., Yahr, M. D., Moros, D. A., Mendoza, M. R., Pang, S. and Bodian, C. A. (1990) L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-DOPA therapy in Parkinson's disease: Experience in 200 patients. In: Advances in Neurology. Vol. 53: Parkinson's Disease: Anatomy, Pathology, and Therapy,. pp. 431-461. Eds. M. B. Streifler, A. D. Korczyn, E. Melamed and M. B. H. Youdim. Raven Press: New York.
53. Elizan T.S., Moros D.A. and Yahr M.D. (1991) Early combination of selegiline and low-dose L DOPA as initial symptomatic therapy in Parkinson's disease experience in 26 patients receiving combined therapy for 26 months. Arch. Neurol. 48, 31-34.
54. Elsworth J.D., Sandler M., Lees A.J., Ward C. and Stern G.M. (1982) The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J. Neural. Transm. 54, 105-110.
55. Factor S.A., Sanchez-Ramos J.R. and Weiner W.J. (1990) Vitamin E therapy in Parkinson's disease. Adv. Neurol. 53, 457-461.
56. Fahn S. (1991) An open trial of high-dosage antioxidants in early Parkinson's disease. Am. J. Clin. Nutr. 53, 380S-382S.
57. Fang J., Zuo D.M. and Yu P.M. (1995) Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone. Life Sci. 57, 15-22.
58. Fearnley J.M. and Lees A. (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114, 2283-2301.
59. Forno L. (1986) The Lewy body in Parkinson's disease. Adv. Neurol. 45, 35-43.
60. Forno L.S. and Alvord E.C.Jr. (1974) Depigmentation in the nerve cells of the substantia nigra and locus ceruleus in Parkinsonism. In: Eds. McDowell, F. H. and Barbeau, A., Second Canadian-American Conference on Parkinson's Disease. Adv. Neurol. 5, 195-202.
61. Gibb W. R. (1991) Neuropathology of the substantia nigra. Eur. Neurol. 31, 48-59.
62. Goeth M.E., Freyberger A. and Riederer P. (1990) Oxidative stress: A role in the pathogenesis of Parkinson's disease. J. Neural. Transm. 29, 241-249.
63. Golbe L.I. and Farrell T. (1988) Case-control survey of early-adult dietary habits in Parkinsons' disease. Neurology 38, 204.
64. Golbe L.I., Langston J.W. and Shoulson I. (1990) Selegiline and Parkinson's disease: Protective and symptomatic consideration. Drugs 39, 646-651.
65. Gottfries C.G. (1985) Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatments. Psychopharmacology 86, 245-252.
66. Graham D.G. (1979) On the origin and significance of neuromelanin. Archs Path. 103, 359-362.
67. Graham D.G., Tiffany S.M., Bell W.R. and Gutknecht W.F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Molec. Pharmacol. 14, 644-653.
68. Graham R.C. and Karnovsky M.J. (1965) The histochemical demonstration of monoamine oxidase by coupled peroxidatic oxidation. J. Histochem. Cytochem. 13, 604-605.
69. Guggenheim M.A., Ringel S.P., Silverman A. and Grabert B.E. (1982) Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with alpha tocopherol. J. Pediat. 100, 51-58.
70. Hadjiconstantinou M., Fitkin J.G., Dalia A. and Neff N.H. (1991) Epidermal growth factor enhances striatal dopaminergic parameters in methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice. J. Neurochem. 57, 479-482.
71. Hagglund J., Aquilonius S.M., Erkernas S.M., Harving P., Lundquist H., Gullberg P. and Langstrom B. (1987) Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using C-N-methyl-spiperone. Acta Neurol. Scan. 75, 87-94.
72. Halliwell B. and Gutteridge J.M.C. (1985) Oxygen radicals and the nervous system. Trends Neurosci. 8, 22-26.
73. Halliwell B. and Gutteridge J.M.C. (1986) Iron and free radical reactions: Two aspects of antioxidant protection. Trends Biol. Sci. 11, 1372-1375.
74. Harding A.E., Muller D.P.R., Thomas P.K. and Willson H.J. (1982) Spinocerebellar degeneration secondary to chronic intestinal malabsorption: a vitamin E deficiency syndrome. Ann. Neurol. 12, 419-424.
75. Harmon D. (1956) Aging: A theory based on free radical and radiation chemistry. J. Gerontol. 11, 298-300.
76. Harmon, D. (1987) The free radical theory of aging. In: Modern Biological Theories of Aging, pp. 81-87. Eds. H. R. Warner, R. N., Butler, R. L. Sprott and E. L. Schneider. Raven Press: New York.
77. Harsing L.G.Jr. and Vizi E.S. (1984) Release of endogenous dopamine from rat isolated striatum: Effect of clorgyline and (-)deprenyl. Br. J. Pharmacol. 83, 741-749.
78. Hattori N., Tanaka M. and Ozawa T. (1991) Immunohistochemical studies in complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30, 563-571.
79. Heikkila R.E., Manzino L., Duvoisin R.C. and Cabbat F.S. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467-469.
80. Heikkila R.E., Nicklas W.L. and Vyas I. (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implications for the mechanism of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine toxicity. Neurosci. Lett. 62, 389-394.
81. Hiramatsu M., Kohno M., Mori A., Shiraga H., Pfeiffer R.F. and Ebadi M. (1994) An ESR study of 6-hydroxydopamine: Generated hydroxy radicals and superoxide anions in brain. Neurosciences 20, 129-138.
82. Hirsch E., Graybiel A.M. and Agid Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 334, 345-348.
83. Horn A.S. (1990) Dopamine uptake: A review of progress in the last decade. Prog. Neurobiol. 34, 397-400.
84. Hornykiewicz O. (1988) Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J. Med. 55, 11-20.
85. Hornykiewicz O. and Kish S.J. (1986) Biochemical pathology of Parkinson's disease. Adv. Neurol. 45, 19-34.
86. Houslay M.D., Tipton K.F. and Youdim M.B.H. (1976) Multiple forms of monoamine oxidase: Fact and artifact. Life Sci. 19, 467-478.
87. Howard L., Oversen L., Satya-Murti S. and Chu R. (1982) Reversible neurological symptoms caused by vitamin E deficiency in a patient with short bowel syndrome. Am. J. clin. Nutr. 36, 1243-1249.
88. Huebers H. and Finch C. (1987) The physiology of transferrin and transferrin receptors. Physiol. Rev. 67, 520-582.
89. Hyman C., Hofer M. and Barde Y.-A. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230-232.
90. Iversen L.L. (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmac. 41, 571-591.
91. Javitch J.A., Uhl G.R. and Snyder S.H. (1984) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and localization of receptor binding sites in rat and human brain. Proc. Natn. Acad. Sci. U.S.A. 81, 4591-4595.
92. Javitch J.A., D'Amato R.J., Strittmatter S.M. and Snyder S.H. (1985) Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natn. Acad. Sci. U.S.A. 82, 2173-2177.
93. Jellinger K. (1986) An overview of morphological changes in Parkinson's disease. Adv. Neurol. 45, 1-16.
94. Jellinger, K. (1987) The pathology of parkinsonism. In: Movement Disorders, pp. 124-165. Eds. C. D. Marsden and S. Fahn. Butterworths: London.
95. Jellinger K. (1990) New developments in the pathology of Parkinson's disease. Adv. Neurol. 53, 1-16.
96. Jenner P., Schapira A.H.V. and Marsden C.D. (1992) New insights into the cause of Parkinson's disease. Neurology 42, 2241-2250.
97. Jesberger J.A. (1991) Oxygen free radicals and brain dysfunction. Int. J. Neurosci. 57, 1-17.
98. Johnston J.P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285-1297.
99. 3H)deprenyl. Brain Res. 547, 69-76.
100. Karoum F., Chuang L.W. and Eisler T. (1982) Metabolism of (-)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32, 503-509.
101. Kish S.J., Morito C. and Hornykiewicz O. (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346.
102. Kishimoto S., Kimura H. and Maeda T. (1983) Histochemical demonstration for monoamine oxidase (MAO) by a new coupled peroxidation method. Cell. Molec. Biol. 29, 61-69.
103. Kitahama K., Arai R., Maeda T. and Jouvet M. (1986) Demonstration of MAO-B in serotoninergic and MAO-A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique. Neurosci. Lett. 71, 19-24.
104. Kitahama K., Kimura H., Maeda T. and Jouvet M. (1987) Distribution of two types of monoamine oxidase-containing cells and fibers in the cat hypothalamus demonstrated by an improved enzyme histochemical method. Neuroscience 20, 991-999.
105. Kitahama K., Sallanon M., Lin J.-S., Maeda T. and Jouvet M. (1989) Type B monoamine oxidase-containing cells and fibers in the cat hypothalamus demonstrated by an improved enzyme histochemical method. J. Comp. Neurol. 285, 218-230.
106. +: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann. Neurol. 32, 109-111.
107. Knoll J. (1983) Deprenyl (selegiline): The history of its development and pharmacological action. Acta Neurol. Scan. 95, 57-80.
108. Knoll J. (1987) Critical role in MAO-inhibition in Parkinson's disease. Adv. Neurol. 45, 107-110.
109. Knoll J. (1987) R-(-)-Deprenyl (selegiline, movergan) facilitates the activity of nigrostriatal dopaminergic neuron. J. Neural. Transm. 25, 45-66.
110. Knoll, J. (1990) Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. In: Advances in Neurology Vol. 53: Parkinson's Disease: Anatomy, Pathology, and Therapy, pp. 425-429. Eds. M. B. Streifler, A. D. Korczyn, A. D. E. Melamed and M. B. H. Youdin. Raven Press: New York.
111. Knoll J. (1992) Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Med. Res. Rev. 12, 505-524.
112. Knoll J. and Magyar K. ( 1972) Some puzzling effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmac. 5, 393-408.
113. Knoll J., Vizi E.S. and Somogyi G. (1968) Phenylisopropylmethyl-propinyl-amine (E-250) a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittel-Forsch. 18, 109-112.
114. Knoll J., Yen T.T. and Dallo J. (1983) Long-lasting, true aphrodisiac effect of (-)-deprenyl in sluggish old male rats. Mod. Prob. Pharmacopsychiat. 19, 135-153.
115. Knusel B., Winslow J.W., Rosenthal A., Burton L.E., Seid D.P., Nikolics K. and Hefti F. (1991) Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. Natn. Acad. Sci. U.S.A. 88, 961-965.
116. Konradi C., Jellinger K., Riederer P., Denney P. and Thibault J. (1988) Topographic immunocyto-chemical mapping of MAO-A, MAO-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26, 791-802.
117. Konradi C., Kornhuber J., Froelich L., Fritze J., Heinsen H., Beckmann H., Schultz E. and Riederer P. (1989) Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33, 383-400.
118. Konradi, C., Riederer, P. and Hensen, H. (1990) Histochemistry of MAO subtypes in the brainstem of humans: A relation of the radical hypothesis of Parkinson's disease? In: Early Diagnosis and Preventative Therapy in Parkinson's Disease, pp. 243-248. Eds. I. Przuntek and P. Riederer. Springer Verlag: Wien.
119. Kopin I.J. (1986) Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Adv. Neurol. 45, 137-144.
120. Kopin I.J. and Schoenberg D.G. (1988) MPTP in animal models of Parkinson's disease. Mt Sinai J. Med. 55, 43-49.
121. Koulu M. and Lammintausta R. (1983) Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): A summary of studies on volunteers. Acta Neurol. Scan. 95, 91-94.
122. Krige D., Carroll M.T., Cooper J.M., Marsden C.D. and Schapira A.H.V. (1992) Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32, 782-788.
123. Kupsch A. and Oertel W.H. (1994) Neural transplantation, trophic factors and Parkinson's disease. Life Sci. 55, 2083-2095.
124. Lai C.T., Zuo D.M. and Yu P.H. (1994) Is brain superoxide dismutase activity increased following treatment with L-deprenyl?. J. Neural Transm. 41, 221-229.
125. Lange K.W. and Riederer P. (1994) Glutamatergic drugs in Parkinson's disease. Life Sci. 55, 2067-2075.
126. Lange S.C., Neafsey E.J. and Wyler A.R. (1980) Neuronal activity in chronic ferric-chloride epileptic foci in cats and monkeys. Epilepsia 21, 251-254.
127. Levitt P., Pintar J.E. and Breakefield X.O. (1982) Immunocytochemical demonstration of MAO-B in brain astrocytes and serotoninergic neurons. Proc. Natn. Acad. Sci. U.S.A. 79, 6385-6389.
128. Liebowitz M.R., Karoum F., Quitkin F.M., Davies S.O., Schwartz D., Levitt M. and Linnoila M. (1985) Biochemical effects of L-deprenyl in atypical depressives. Biol. Psychiat. 20, 558-565.
129. Louis E.D., Goldman J.E., Powers J.M. and Fahn S. (1995) Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov. Disord. 10, 188-194.
130. Maeda T., Kimura H., Nagai T., Imai H., Arai R., Sakumoto T., Sakai K., Kitahama K. and Jouvet M. (1984) Histochemistry of the magnocellular neurons in the posterior hypothalamus, with special reference to MAO activity and ability of 5HT to uptake and decarboxylation. Acta Histochem. Cytochem. 17, 179-193.
131. Maeda T., Imai H., Arai R., Tago H., Nagai T., Sakumoto T., Kitahama K., Onteniente B. and Imura H. (1987) An improved coupled peroxidatic oxidation method of MAO histochemistry for neuroanatomical research at light and electron microscopic levels. Cell. molec. Biol. 33, 1-11.
132. Malessa S., Hirsch E.C., Cervera P., Duyckaerts C. and Agid Y. (1990) Catecholaminergic systems in the medulla oblongata in Parkinsonian syndromes. Neurology 40, 1739-1743.
133. Mallinger A.G. and Smith E. (1991) Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmac. Bull. 27, 493-502.
134. Málly J. (1992) Some new aspects of the effect of (-)deprenyl in Parkinson's disease - a retrospective study. J. Neural. Transm. 4, 155-164.
135. Mangoni A., Grassi M.P., Frattola L., Piolti R., Bassi S., Motta A., Marcone A. and Smirne S. (1991) Effects of a MAO B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 31, 100-107.
136. Mann D.M.A. and Yates P.O. (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21, 193-203.
137. Mann D.M.A., Yates P.O. and Barton C.M. (1977) Neuromelanin and RNA in cells of substantia nigra. J. Neuropath. Exp. Neurol. 36, 379-384.
138. Marsden C.D. (1983) Neuromelanin and Parkinson's disease. J. Neural. Transm. 19, 121-141.
139. Mash D., Pablo J., Buck B., Sanchez-Ramos J. and Weiner W. (1991) Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Expl Neurol. 114, 73-81.
140. Mash, D. C., Singer, J., Pablo, J., Basile, M., Bruce, J. and Weiner, W. J. (1993) Iron storage and transport markers in Parkinson's disease and MPTP-treated mice. In: Iron in Central Nervous System Disorders, pp. 103-116. Eds. P. Riederer and M. B. Youdim. Springer-Verlag: Wien.
141. McCay P.B., Pfeifer P.M. and Stipe W.H. (1972) Vitamin E protection of membrane lipids during electron transport functions. Ann. N. Y. Acad. Sci. 203, 62-73.
142. McNeill T., Brown S., Rafols J. and Shoulson I. (1988) Atrophy of medium spiny-I striatal dendrites in advanced Parkinson's disease. Brain Res. 455, 148-152.
143. Meeker J.E. and Reynolds P.C. (1990) Postmortem tissue methamphetamine concentrations following selegiline administration. J. Anal. Toxic. 14, 330-331.
144. Melamed E., Rosenthal J. and Globus M. (1985) Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res. 342, 401-404.
145. Mena M.A., Pardo B., Casarejos M.J., Fahn S. and Garcia de Yebenes J. (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov. Disord. 7, 23-31.
146. +, inhibit mitochondrial NADH-ubiquinone oxidoreductase activity. Proc. Japan Acad. Series B -Phys. Biol. Sci. 62, 261-263.
147. Mitzuno Y., Sone N. and Saitoh T. (1987) Effects of 1-methyl-4-phenyl-1,2,3,60tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48, 1787-1793.
148. +) against mitochondria of mouse brain. J. Neurol. Sci. 86, 97-110.
149. Mitzuno Y., Ohta S. and Tanaka M. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455.
150. Mitzuno Y., Suzuki K. and Ohta S. (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J. Neurol. Sci. 96, 49-57.
151. Mitzuno Y., Mori H. and Kondo T. (1994) Potential of neuroprotective therapy in Parkinson's disease. CNS Drugs 1, 45-56.
152. Muller, D. P. R., Lloyd, J. F. and Wolff, O. H. (1983) Vitamin E and neurological function. In: Abetalipoproteinaemia and Other Disorders of Fat Absorption. Biology of Vitamin E, pp. 106-121. CIBA Foundation Symposium #101.
153. +) is toxic to mesencephalic dopamine neurons in culture. Neurosci. Lett. 57, 19-24.
154. Naoi M. and Maruyama W. (1993) Type B monoamine oxidase and neurotoxins. Eur. Neurol. 33, 31-37.
155. Okazawa H., Murata M., Watanabe M., Kamei M. and Kanazawa I. (1992) Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. Fedn Eur. biochem. Soc. 313, 138-142.
156. Olney J.W., Price M.T. and Labruyere J. (1987) Anti-Parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. Eur. J. Pharmac. 142, 319-320.
157. Parker W.D.Jr., Boyson S.J. and Park J.K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
158. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability of early Parkinson's disease. New Engl. J. Med. 328, 176-183.
159. 3H-MPTP may correspond to MAO. Eur. J. Pharmacol. 102, 375-377.
160. Perry T.L. and Young V.W. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
161. Perry T.L., Godin D.V. and Hansen S. (1982) Parkinson's disease: A disorder due to nigral glutathione deficiency?. Neurosci. Lett. 33, 305-310.
162. Prochiantz A., Di Porzio U., Kato A., Berger B. and Glowinski J. (1979) In vitro maturation of mesencephalic dopaminergic neurons from mouse embryos is enhanced in presence of their striatal target cells. Proc. Natn. Acad. Sci. U.S.A. 76, 5387-5391.
163. Pryor, W. A. (1987) The free-radical theory of aging revisited: A critique and a suggested disease-specific theory. In: Modern Biological Theories of Aging, pp. 89-112. Eds. H. R. Warner, R. N. Butler, R. L. Sprott and E. L. Schneider. Raven Press: New York.
164. 3H-pargyline binding to MAO. Brain Res. 330, 337-343.
165. Ramsay R.R., Salach J.I. and Dadgar J. (1986) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism. Biochem. Biophys. Res. Commun. 135, 269-273.
166. Reynolds G.P., Riederer P., Sandier M., Jellinger K. and Seemann D. (1978) Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural. Transm. 43, 271-277.
167. Reynolds G.P., Riederer P. and Sandler M. (1979) 2-Phenylethylamine and amphetamine in human brain: Effects of L-deprenyl in Parkinson's disease. Biochem. Soc. Transm. 7, 143-145.
168. Ricaurte G.A., Langston J.W. and Delanney L.E. (1985) Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci. Lett. 59, 259-264.
169. 3H]Ro 19-6327: Localization of MAO-B in rat CNS, peripheral organs and human brain. Pharmacol. Res. Commun. 20, 91-92.
170. Richards J.G., Saura J., Ulrich J. and DaPrada M. (1992) Molecular neuroanatomy of monoamine oxidases. Psychopharmacology 106, 21-23.
171. Richardson J.S., Subbarao K.V. and Ang L.C. (1990) Biochemical indices of peroxidation in Alzheimer's and control brains. Trans. Am. Soc. Neurochem. 21, 113.
172. Riederer P. and Jellinger K. (1983) Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta Neurol. Scand. 95, 43-55.
173. Riederer P. and Youdim M.B.H. (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J. Neurochem. 46, 1359-1365.
174. Riederer P., Rausch W.D., Schmidt B., Kruzik P., Konradi C., Sofia E., Danielczyk W., Fisher M. and Ogris E. (1988) Biochemical fundamentals of Parkinson's disease. Mt. Sinai J. Med. 55, 21-28.
175. Riederer P., Konradi C., Hebenstreit G. and Youdim M.B.H. (1989) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol. Scand. 80, 41-45.
176. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K. and Youdim M.B.H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brain. J. Neurochem. 52, 515-520.
177. Rinne U.K., Rinne J.O., Laasko K., Laihinen A. and Lonnberg P. (1983) Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J. Neural. Transm. 18, 279-286.
178. Rojas-Castaneda P., Cerutis D.R., Blaxall H.S., Happe H.K., Murrin L.C. and Ebadi M. (1994) Protective effects of zinc and metallothionein in oxygen free radical-mediated oxidative stress in brain. Soc. Neurosci. Abstr. 24, 2.
179. Roselaar S.E., Langdon N., Lock C.B., Jenner P. and Parkes J.D. (1987) . Selegiline in narcolepsy. Sleep 10, 491-495.
180. Rosenblum J.L., Keating J.P., Prensky A.L. and Nelson J.S. (1981) A progressive neurologic syndrome in children with chronic liver disease. New Engl. J. Med. 304, 503-508.
181. Rowland L.P. (1983) Molecular genetics, pseudogenetis, and clinical neurology. Neurology (Cleveland) 33, 1179-1195.
182. Saggu H., Cooksey J. and Dexter D. (1989) A selective increase in particulate superoxide dismutase activity in Parkinsonian-substantia nigra. J. Neurochem. 53, 692-697.
183. Saitoh T. (1988) Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl. J. Neurol. Sci. 83, 161-166.
184. Sato M. and Bremner I. (1993) Oxygen free radicals and metallothionein. Free Rad. Biol. Med. 14, 325-337.
185. Satya-Murti S., Howard L., Krohel G. and Wolf B. (1986) The spectrum of neurologic disorder from vitamin E deficiency. Neurology 36, 917-921.
186. Saura Marti J., Kettler R., DaPrada M. and Richards J.G. (1990) Molecular neuroanatomy of MAO-A and MAO-B. J. Neural. Transm. 32, 49-53.
187. Schapira A.H.V., Cooper J.M. and Dexter D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
188. Schapira A.H.V., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B. and Marsden C.D. (1990) Anatomic and disease specificity of NADH CoQ reductase (complex 1) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145.
189. Schapira A.H.V., Mann V.M., Hartley A., Cooper J.M., Daniel S.E. and Marsden C.D. (1993) Complex 1 deficiency in Parkinson's disease. Mov. Disord. 8, 403-404.
190. Semchuk K.M., Love E.J. and Lee R.G. (1993) Parkinson's disease: A test of the multifactoral etiologic hypothesis. Neurology 43, 1173-1180.
191. Shiraga H., Pfeiffer R.F. and Ebadi M. (1993) The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem. Int. 23, 561-566.
192. Shoulson I. (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur. Neurol. 32, 46-53.
193. Shoulson I. and Fahn S. (1993) Effects of tocopherol and deprenyl on the progression of disability of early Parkinson's disease. New Engl. J. Med. 328, 176-183.
194. Singer T.P., Castagnoli N., Ramsay R.R. and Trevor A.J. (1987) Biochemical events in development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine. J. Neurochem. 49, 1-8.
195. Sitges M., Reyes A. and Chiu L.M. (1994) Dopamine transporter mediated release of dopamine: Role of chloride. J. Neurosci. Res. 39, 11-22.
196. Smith, T. S., Parker, W. D., Jr and Bennett, J. P., Jr (1994) L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity? NeuroReport. 5, 1009-1011.
197. Snyder S.H. and D'Amato R.J. (1986) MPTP: A neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36, 250-258.
198. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds C.P., Hebenstreit G. and Youdim M.B.H. (1988) Increased iron (III) and total iron content in post-mortem substantia nigra of Parkinsonian brain. J. Neural Transm. 74, 199-205.
199. Sofic E., Paulus W., Jellinger K., Riederer P. and Youdim M.B.H. (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J. Neurochem. 56, 978-982.
200. Sofic E., Lange K.W., Jellinger K. and Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
201. Sourkes T.L. (1970) On the mode of action of L-DOPA in Parkinson's disease. Biochem. Med. 3, 321-325.
202. Spatz H. (1922) Über den Eisennachweis im Gehirn, besonders in Zentren des extrapyramidal-motorischen systems. Z. ges Neurol. Psychiat. 77, 261-390.
203. Spina M.B. and Cohen G. (1989) Dopamine turnover and glutathione oxidation. Implications for Parkinson's disease. Proc. Natn. Acad. Sci. U.S.A. 86, 1398-1400.
204. Spina M.B., Squinto S.P. and Miller J. (1992) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J. Neurochem. 59, 99-106.
205. Stern G.M. (1987) Vitamin E and Parkinson's disease. Lancet 1, 508.
206. Stern G.M., Lees A.J. and Sandler M. (1978) Recent observations on the clinical pharmacology of (-)-deprenyl. J. Neural. Transm. 43, 245-251.
207. Stern G.M., Lees A.J., Hardie R.J. and Sandler M. (1983) Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Acta Neurol. Scand. 95, 113-116.
208. Tanaka M., Sotomatsu A., Kanai H. and Hirai S. (1992) Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron. Neurosci. Lett. 140, 42-46.
209. Tatton W.G. (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov. Disord. 8, S20-S30.
210. Tatton W.G., Greenwood C.E., Salo P. and Seniuk N.A. (1991) Transmitter synthesis increase in substantia nigra neurons in aged mice. Neurosci. Lett. 31, 179-182.
211. Tekes K., Tóthfalusi L., Gaál J. and Magyar K. (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol. J. Pharmacol. Pharm. 40, 653-658.
212. Tetrud J.W. and Langston J.W. (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245, 519-522.
213. Thorpe L.W., Westlund K.N., Kochersperger L.M., Abell C.W. and Denney R.M. (1987) Immunocytochemical localization of MAO-A and -B in human peripheral tissues and brain. J. Histochem. Cytochem. 35, 23-32.
214. Tooyama I., Kawamata T. and Walker D. (1993) Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43, 372-376.
215. Torbati D., Church D.F., Keller J.M. and Pryor W.A. (1992) Free radical generation in the brain precedes hyperbaric oxygen-induced convulsions. Free Rad. Biol. Med. 13, 101-106.
216. ++ injection. J. Neurochem. 42, 976-980.
217. Turkish S., Yu P. and Greenshaw A.J. (1988) Monoamine oxidase-B inhibition: A comparison of in vivo and ex vivo measures of reversible effects. J. Neural. Transm. 74, 141-148.
218. Uhl G.R. (1990) Parkinson's disease: Neurotransmitter and neurotoxin receptors and their genes. Eur. J. Neurol. 30, 21-30.
219. Uhl G.R., Hedreen J.C. and Price D.L. (1985) Parkinson's disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35, 1215-1218.
220. Uhl G.R., Walther D., Mash D., Faucheux B. and Javoy-Agid F. (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-498.
221. Van Der Vliet A. and Bast A. (1992) Effect of oxidative stress on receptors and signal transmission. Chem. Biol. Interactions. 85, 95-116.
222. Vincent S.R. (1989) Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain. Neuroscience 28, 189-199.
223. Vizi E.S., Harsing L.G.Jr. and Knoll J. (1977) Presynaptic inhibition leading to disinhibition of acetylcholine release from interneurons of the caudate nucleus: Effects of dopamine, beta-endorphin, and D-Ala 2-Pro 5 enkephalinamide. Neuroscience 2, 953-961.
224. Wakamatsu K., Ito S. and Nagatsu T. (1991) Cysteinyldopamine is not incorporated into neuromelanin. Neurosci. Lett. 131, 57-60.
225. Warren J.S., Johnson K.J. and Ward P.A. (1987) Oxygen radicals in cell injury and cell death. Pathol. Immunopathol. Res. 6, 301-315.
226. Weder B., Meinberg O., Wildi E. and Meier C. (1984) Neurologic disorder of vitamin E deficiency in acquired intestinal malabsorption. Neurology (Cleveland) 334, 1561-1565.
227. Weihmuller F.B., Ulas J., Nguyen L., Cotman C.W. and Marshall J.F. (1992) Elevated NMDA receptors in Parkinsonian striatum. NeuroReport. 3, 977-980.
228. Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M. and Abell C.W. (1985) Distinct MAO A and MAO B populations in the primate brain. Science 230, 181-183.
229. Westlund K.N., Denney R.M., Rose R.M. and Abell C.W. (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456.
230. Weyler W. and Salach J.I. (1985) Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J. Biol. Chem. 260, 13199-13207.
231. Wick M., Byers L. and Frey E. (1977) L-DOPA: Selective toxicity for melanoma cells In vitro. Science 197, 468-469.
232. Willoughby J., Glover V. and Sandler M. (1988) Histochemical localisation of MAO-A and -B in rat brain. J. Neural. Transm. 74, 29-42.
233. Yehuda, S. and Youdim, M. B. H. (1988) Brain iron deficiency. Biochemistry and behaviour. In: Brain Iron Neurochemical and Behavioural Aspects, pp. 89-114. Ed. M. B. H. Youdim. Taylor Francis: London.
234. Yoshikawa T. (1993) Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33, 60-68.
235. Youdim M.B.H. (1978) The active centers of monoamine oxidase types A and B: Binding with (14C)-clorgyline and (14C)-deprenyl. J. Neural. Transm. 43, 199-208.
236. Youdim M.B.H. (1986) Pharmacology of MAO-B inhibitors: Mode of action of (-) deprenyl in Parkinson's disease. J. Neural. Transm. 22, 91-105.
237. Youdim M.B.H. (1989) Brain monoamine oxidase (MAO)B: A unique neurotoxin and neurotransmitter producing enzyme. Prog. Neuropsychopharmac. Biol. Psychiat. 13, 363-371.
238. Youdim M.B.H. and Finberg J.P.M. (1991) New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem. Pharmacol. 41, 155-162.
239. Youdim M.B.H. and Lavie L. (1994) Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 55, 2077-2082.
240. Youdim M.B.H., Collins G.G.S. and Sandier M. (1971) Monoamine oxidase multiple forms and selective inhibitors. Biochem. J. 121, 34-36.
241. Youdim, M. B. H., Ben-Shachar, D., Ashkenazi, R. and Yehuda, S. (1985) Brain iron and dopamine receptor function. In: CNS Receptors: From Molecular Pharmacology to Behavior, pp. 309-322. Eds. P. Mandel, F. V. De Feudis. Raven Press: New York.
242. Youdim M.B.H., Ben-Shachar D. and Riederer P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta neurol. Scand. 26, 47-54.
243. Youdim, M. B. H., Ben-Shachar, D., Yehuda, S. and Riederer, P. (1990) The role of iron in the basal ganglion. In: Advances in Neurology. Parkinson's Disease: Anatomy, Pathology, and Therapy, pp. 155-162. Eds. B. M. Streifler, A. D. Korczyn, E. Melamed and M. B. H. Youdim. Raven Press: New York.
244. Youngster S.K., McKeown K.A., Jin Y.Z., Ramsay R.R., Heikkila R.E. and Singer T.P. (1989) Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem. 53, 1837-1842.
245. Yurek D.M. and Sladek J.R. (1990) Dopamine cell replacement: Parkinson's disease. Ann. Rev Neurosci. 13, 415-440.
246. Zecca L., Pietra R., Goj C., Mecacci C., Radice D. and Sabbioni E. (1994) Iron and other metals in neurometanin, substantia nigra, and putamen of human brain. J. Neurochem. 62, 1097-1101.
247. Zhang Z.-X. and Roman G.C. (1993) Worldwide occurrence of Parkinson's disease: An updated review. Neuroepidemiology 12, 195-208.